Feasibility of circulating miRNA microarray analysis from archival plasma samples

被引：22

作者：

Callari, Maurizio ^{[1
,2
]}

Tiberio, Paola ^{[1
]}

De Cecco, Loris ^{[2
]}

Cavadini, Elena ^{[1
]}

Dugo, Matteo ^{[2
]}

Ghimenti, Chiara ^{[3
]}

Daidone, Maria Grazia ^{[1
]}

Canevari, Silvana ^{[2
,4
]}

Appierto, Valentina ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Unit Biomarkers, Dept Expt Oncol & Mol Med, I-20133 Milan, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Funct Genom Core Facil, I-20133 Milan, Italy

[3] Edo & Elvo Tempia Fdn, Canc Genom Lab, Biella, Italy

[4] Fdn IRCCS Ist Nazl Tumori, Unit Mol Therapies, Dept Expt Oncol & Mol Med, I-20133 Milan, Italy

来源：

ANALYTICAL BIOCHEMISTRY | 2013年 / 437卷 / 02期

关键词：

miRNA; Plasma; Blood; Circulating miRNA; Agilent; Microarray; MICRORNAS; FENRETINIDE; CANCER; TRIAL; SERUM;

D O I：

10.1016/j.ab.2013.03.002

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

MicroRNAs have been found to be deregulated in several diseases and, due to their high stability in body fluids, represent promising noninvasively detectable biomarkers. However, numerous technical variables can affect accurate measurement of circulating miRNAs. Using a microarray-based method we assessed the: (i) adequate intra- and inter-array reproducibility of miRNA profiling; (ii) feasibility of using archival plasma samples stored for an extended period of time and available in limited amounts; (iii) good correlation between different batches; and (iv) time-dependent increase of background signals close to the chip expiration date. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：123 / 125

页数：3

共 14 条

[11] MicroRNA Detection in Plasma Samples How to Treat Heparinized Plasma Reply
Duelli, Dominik M.
Palma, Jaime
Beaman, Kenneth
Hastings, Michelle L.
Kwak-Kim, Joanne
Linnstaedt, Sarah
Park, Joon Cheol
Kim, Dong-Ja
[J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (01) : 138 - 139
[12] Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer
Veronesi, U.
Mariani, L.
Decensi, A.
Formelli, F.
Camerini, T.
Miceli, R.
Di Mauro, M. G.
Costa, A.
Marubini, E.
Sporn, M. B.
De Palo, G.
[J]. ANNALS OF ONCOLOGY, 2006, 17 (07) : 1065 - 1071
[13] Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
Veronesi, U
De Palo, G
Marubini, E
Costa, A
Formelli, F
Mariani, L
Decensi, A
Camerini, T
Del Turco, MR
Di Mauro, MG
Muraca, MG
Del Vecchio, M
Pinto, C
D'Aiuto, G
Boni, C
Campa, T
Magni, A
Miceli, R
Perloff, M
Malone, WF
Sporn, MB
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (21) : 1847 - 1856
[14] Comparing the MicroRNA Spectrum between Serum and Plasma
Wang, Kai
Yuan, Yue
Cho, Ji-Hoon
McClarty, Sara
Baxter, David
Galas, David J.
[J]. PLOS ONE, 2012, 7 (07):

← 1 2 →